NOURNEWS-
Orlando Pérez Rodríguez, director of Science and Innovation at BioCubaFarma, said that all clinical research and interventions have been duly authorized by Cuban regulatory entities and will be timely evaluated and reported to publicize Cuba's experience in this field.
He explained that 6 of the 15 projects are focused on treatment, the same number are prophylactic, two are diagnosticians and a medical team.
He added that the products focus on increasing people's innate immunity, reducing the viral load at the beginning of the disease and reducing the hyperinflammatory reaction in patients who develop it, especially in vulnerable groups (older adults or those with pathologies of antecedent).
As a sample of the responsiveness of Cuban Biotechnology, 9 of these projects are already in the phase of intervention trials or clinical studies and six are still in the research and development phase in laboratories, in addition to others in the design or early research.
He pointed out that in the treatment, in the initial stage Interferon Alpha 2B is used, for the management of the inflammatory reaction produced by Covid-19, the monoclonal antibody of the Immunoassay Center and a peptide from the Center for Genetic and Biotechnological Engineering are studied (CIGB).
Most products focus on the use of prophylactics, including nasal administration of interferon Alfa (to stimulate immunity), biomodulin-T (for those over 60 years of age), transfer factor (stimulates immunity in vulnerable groups) , CIGB 2020 (immuno enhancer) and a vaccine candidate from the Finlay Institute (contains components of the Cuban meningitis vaccine).
He added that among the projects that are in the research phase are two anti-viral peptides, a vaccine to induce specific protective immunity in case of a re-emergence of the disease, as well as the design of lung ventilators by the CNEURO and COMBIOMED. , some of whose pieces would be obtained through 3D printing.
Regarding the diagnosis, Pérez Rodríguez mentioned a test developed by the Immunoassay Center to detect the presence of antibodies in patients mounted on SUMA technology (there are more than three thousand teams of this technology in the country that allow technology sovereignty and broad coverage).
The official stressed that this response from Cuban biotechnology is possible due to the vision of Commander in Chief Fidel Castro, who created the scientific pole of Biotechnology in the 80s and 90s of the last century, which allowed the creation of a product portfolio. for different diseases and technologies that are used today in light of international experiences in the fight against Covid-19. (ACN)
Cuban News Agency